KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) FCF Margin (2016 - 2025)

Rigel Pharmaceuticals has reported FCF Margin over the past 15 years, most recently at 31.51% for Q4 2025.

  • For Q4 2025, FCF Margin rose 637.0% year-over-year to 31.51%; the TTM value through Dec 2025 reached 25.71%, up 817.0%, while the annual FY2025 figure was 25.71%, 817.0% up from the prior year.
  • FCF Margin for Q4 2025 was 31.51% at Rigel Pharmaceuticals, down from 34.6% in the prior quarter.
  • Over five years, FCF Margin peaked at 208.67% in Q2 2021 and troughed at 154.53% in Q1 2022.
  • A 5-year average of 6.6% and a median of 10.23% in 2023 define the central range for FCF Margin.
  • Biggest five-year swings in FCF Margin: surged 29602bps in 2021 and later crashed -25185bps in 2022.
  • Year by year, FCF Margin stood at 93.41% in 2021, then soared by 54bps to 42.87% in 2022, then soared by 59bps to 17.43% in 2023, then skyrocketed by 244bps to 25.14% in 2024, then rose by 25bps to 31.51% in 2025.
  • Business Quant data shows FCF Margin for RIGL at 31.51% in Q4 2025, 34.6% in Q3 2025, and 30.03% in Q2 2025.